

Company Name	3 - D Matrix, Ltd.
Address	3-2-4, Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

[Delayed] Amicable Settlement of Litigation and Recognition of Extraordinary Loss

(This original disclosure in Japanese was released on August 8, 2014 at 16:30 (GMT+9))

3-D Matrix, Ltd. (the “company”) reached an amicable settlement with respect to the litigation seeking compensation for damages filed by OncoTherapy Science Inc. (hereinafter, “Plaintiff”) on August 8, 2014 as follows. As a result, we expect to recognize an extraordinary loss incurred from the settlement.

1. Overall progress up to date

The litigation has been filed by Plaintiff concerning the unpaid partial consideration for the performance of operations in Japan specified in the advisory contract made between Plaintiff and the company.

Taking into consideration the discussion made at the court as well as the potential of significant income improvement in the medium and long terms after the discharge of obligation to pay consideration in the future, the company agreed an amicable settlement at the court as of August 8, 2014.

2. Description of Plaintiff

- | | |
|---------------------------------|--|
| (1) Company name: | OncoTherapy Science Inc. |
| (2) Address: | 3-2-1 Sakado, Takatsu-ku, Kawasaki-shi, Kanagawa |
| (3) Name of the representative: | Kazuo Yamamoto, President |

3. Content of amicable settlement

We reached an amicable settlement of the litigation by agreeing the payment of settlement money concerning the payment of consideration in question. Please understand that we are unable to disclose the details of settlement negotiations based on our agreement with Plaintiff.

4. Future progress

We will recognize an extraordinary loss of 160 million yen as settlement money in the first quarter of FY2015. We are now examining the impact of the loss including dispute costs on the financial forecasts for FY2015, and will announce the outcome as soon as possible.

In addition, we expect the effect of cost reduction in the medium and long terms as a result of the amicable settlement, for which we are also examining the impact on our Mid-Term Business Plan in FY2016 and thereafter and will announce the outcome immediately after the completion of the examination.